ASH Highlights

Pembrolizumab, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 2 Study

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Daratumumab plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of the GEN503 Study

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Dose-Finding Phase 2 Trial of Single-Agent Isatuximab in Relapsed/Refractory Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Lenalidomide Maintenance in Patients with Relapsed DLBCL Who Cannot Be Treated with Consolidative Transplantation

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Health-Related Quality-of-Life Assessment of Obinutuzumab plus Bendamustine versus Bendamustine in Patients with Rituximab-Refractory Indolent NHL: Results of the GADOLIN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Effect of Ibrutinib versus Temsirolimus Treatment on Lymphoma Symptoms in Patients with Previously Treated Mantle-Cell Lymphoma (MCL): Results of the RAY (MCL3001) Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Page 8 of 15

5
6
7
8
9
10
11